A New Endemic of Concomitant Nonalcoholic Fatty Liver Disease and Chronic Hepatitis B
| Autor: | Mukarram Jamat Ali, Jinendra Satiya, Muzammil Khan, Aysha Aslam, Hira Hanif, Daryl T.-Y. Lau, Pir Meher Ali Shah |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Microbiology (medical)
medicine.medical_specialty Cirrhosis serum biomarkers Review controlled attenuation parameter (CAP) Chronic liver disease medicine.disease_cause Microbiology digestive system Gastroenterology 03 medical and health sciences Liver disease 0302 clinical medicine Virology Internal medicine nonalcoholic steatohepatitis (NASH) transient elastography (Fibroscan) Nonalcoholic fatty liver disease Epidemiology medicine chronic hepatitis B lcsh:QH301-705.5 nonalcoholic fatty liver disease (NAFLD) Hepatitis B virus medicine.diagnostic_test business.industry allergology nutritional and metabolic diseases medicine.disease digestive system diseases magnetic resonance technology lcsh:Biology (General) NAFLD therapy 030220 oncology & carcinogenesis Liver biopsy Hepatocellular carcinoma 030211 gastroenterology & hepatology business |
| Zdroj: | Microorganisms Microorganisms, Vol 8, Iss 1526, p 1526 (2020) |
| Popis: | Hepatitis B virus (HBV) infection remains a global public problem despite the availability of an effective vaccine. In the past decades, nonalcoholic fatty liver disease (NAFLD) has surpassed HBV as the most common cause of chronic liver disease worldwide. The prevalence of concomitant chronic hepatitis B (CHB) and NAFLD thus reaches endemic proportions in geographic regions where both conditions are common. Patients with CHB and NAFLD are at increased risk of liver disease progression to cirrhosis and hepatocellular carcinoma. Due to the complexity of the pathogenesis, accurate diagnosis of NAFLD in CHB patients can be challenging. Liver biopsy is considered the gold standard for diagnosing and determining disease severity, but it is an invasive procedure with potential complications. There is a growing body of literature on the application of novel noninvasive serum biomarkers and advanced radiological modalities to diagnose and evaluate NAFLD, but most have not been adequately validated, especially for patients with CHB. Currently, there is no approved therapy for NAFLD, although many new agents are in different phases of development. This review provides a summary of the epidemiology, clinical features, diagnosis, and management of the NAFLD and highlights the unmet needs in the areas of CHB and NAFLD coexistence. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|